Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Baxter
McKinsey
Mallinckrodt

Last Updated: August 15, 2022

Investigational Drug Information for Fotemustine


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Fotemustine?

Fotemustine is an investigational drug.

There have been 18 clinical trials for Fotemustine. The most recent clinical trial was a Phase 3 trial, which was initiated on March 29th 2021.

The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Lymphoma. The leading clinical trial sponsors are Mingzhi Zhang, Bristol-Myers Squibb, and Zhengzhou University.

There is one US patent protecting this investigational drug and sixteen international patents.

Recent Clinical Trials for Fotemustine
TitleSponsorPhase
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System LymphomaMingzhi ZhangPhase 4
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System LymphomaMingzhi ZhangPhase 4
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGenenta SciencePhase 1/Phase 2

See all Fotemustine clinical trials

Clinical Trial Summary for Fotemustine

Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine

See all Fotemustine clinical trials

US Patents for Fotemustine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fotemustine See Plans and Pricing Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC) See Plans and Pricing
Fotemustine See Plans and Pricing Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
Fotemustine See Plans and Pricing Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA) See Plans and Pricing
Fotemustine See Plans and Pricing Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) See Plans and Pricing
Fotemustine See Plans and Pricing Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fotemustine

Drugname Country Document Number Estimated Expiration Related US Patent
Fotemustine World Intellectual Property Organization (WIPO) WO2015148714 2034-03-25 See Plans and Pricing
Fotemustine Australia AU2015231053 2034-03-21 See Plans and Pricing
Fotemustine Brazil BR112016021620 2034-03-21 See Plans and Pricing
Fotemustine Canada CA2943339 2034-03-21 See Plans and Pricing
Fotemustine China CN106231900 2034-03-21 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.